10-K: Trulieve Cannabis Navigates Federal Rescheduling, Boosts EBITDA

Trulieve Cannabis Corp. reports a slight revenue dip but improved net loss and increased Adjusted EBITDA for 2025, while actively managing debt and anticipating federal cannabis reclassification.

Summary

• Revenue for the year ended December 31, 2025, was $1.18 billion, a slight decrease of 0.4% from $1.19 billion in 2024, primarily due to a $18.4 million decrease in retail revenue, partially offset by a $13.1 million increase in wholesale and other revenue.
• Net loss improved to $(122.2) million in 2025 from $(160.6) million in 2024, reflecting a 23.9% improvement.
• Adjusted EBITDA increased by 1.7% to $427.3 million in 2025 from $420.2 million in 2024, with Adjusted EBITDA as a percentage of revenue rising to 36.2% from 35.4%.
• Cash provided by operating activities saw a modest increase to $272.8 million in 2025 from $271.5 million in 2024.
• The company completed the full redemption of its outstanding $368.0 million 8.0% Senior Secured Notes due 2026 in December 2025, using approximately $373.0 million in cash.
• The Blue Ridge Bank mortgage note, totaling approximately $15.8 million, was fully repaid in December 2025.
• Trulieve closed a private placement of $140.0 million 10.5% Senior Secured Notes due 2030 in December 2025, with an additional $60.0 million tranche closed in January 2026.
• The federal government announced its intention to fast-track the reclassification of marijuana to Schedule III under the Controlled Substances Act in December 2025 via an Executive Order by President Donald Trump.
• Trulieve received conditional approval for a Dispensing Organization license under the Texas Compassionate Use Program in December 2025.
• Ohio legalized adult-use cannabis in 2023, and Trulieve's retail sales in Ohio increased in 2025 due to the market transition from medical-only.
• Ohio Governor Mike DeWine signed a bill into law in December 2025, effective March 20, 2026, limiting the maximum number of operational licensed dispensaries to 400 and eliminating the cannabis social equity and jobs program.
• The company operates 233 dispensaries and 15 cultivation and processing facilities across nine states as of December 31, 2025.
• Uncertain tax position liabilities, primarily related to IRC Section 280E, increased to $668.4 million in 2025 from $445.2 million in 2024, with proposed penalties of approximately $38.1 million being contested.
• The company maintains cash deposits in excess of federally insured limits, posing a banking risk due to the federal illegality of cannabis.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to improved profitability metrics (net loss, Adjusted EBITDA), proactive debt management, and the highly significant federal reclassification news. While revenue growth was flat and tax uncertainties persist, the potential for federal regulatory relief outweighs these concerns, positioning the company for future upside.

Positives

• Net loss improved by 23.9% year-over-year, indicating better cost management and operational efficiency.
• Adjusted EBITDA increased by 1.7% to $427.3 million, with an improved margin of 36.2% of revenue, demonstrating stronger core business performance.
• Successful debt management, including the full redemption of $368.0 million in 8.0% Senior Secured Notes and repayment of a $15.8 million mortgage note, reduces near-term debt obligations.
• Secured new financing with $140.0 million (and an additional $60.0 million in Jan 2026) in 10.5% Senior Secured Notes due 2030, extending maturity profiles.
• President Trump's Executive Order to fast-track cannabis reclassification to Schedule III is a significant positive for the industry, potentially easing federal restrictions and tax burdens.
• Conditional approval for a Texas Dispensing Organization license opens a new market for expansion.
• Increased retail sales in Ohio due to the transition to an adult-use and medical market highlights successful adaptation to regulatory changes.
• The company maintains a strong market-leading retail presence in key states like Arizona, Florida, Georgia, Pennsylvania, and West Virginia.

Negatives

• Total revenue experienced a slight decrease of 0.4% in 2025 compared to 2024, primarily driven by a $18.4 million decrease in retail revenue.
• Price compression in the retail segment negatively impacted revenue despite higher traffic and units sold.
• Uncertain tax position liabilities increased significantly to $668.4 million, with an additional $38.1 million in proposed penalties being contested, indicating ongoing tax-related financial exposure.
• The provision for income taxes increased by 5.3% to $208.1 million, driven by higher interest expense on uncertain tax positions.
• Loss on debt extinguishments of $1.7 million was recorded in 2025, compared to zero in 2024.
• Ohio's new bill limiting dispensaries to 400 and eliminating the social equity program could impact future market dynamics and competition.

Risks

• Cannabis remains illegal under U.S. federal law, posing a significant risk of federal enforcement despite state-level legalization.
• Uncertainty regarding the regulation of cannabis in the U.S. could lead to delays in market development or changes in operational capabilities.
• Constraints on marketing products due to varying state laws may hinder business development and market share competition.
• The ability to grow product offerings and dispensary services may be limited by competitive and regulatory environments in new markets.
• Risks related to material acquisitions, investments, dispositions, and other strategic transactions, including integration challenges and unforeseen liabilities.
• Inability to effectively manage growth could adversely affect business, financial condition, and results of operations.
• Restricted access to banking and other financial services by cannabis businesses due to federal anti-money laundering laws.
• Maintaining cash deposits in excess of federally insured limits exposes the company to banking system disruptions and potential liquidity issues.
• Restrictions under U.S. border entry laws could impact employees, directors, officers, and investors involved in the U.S. cannabis industry.
• Heightened scrutiny in Canada and the United States could adversely impact the liquidity of Subordinate Voting Shares.
• Significant ongoing costs and obligations related to infrastructure, growth, regulatory compliance, and operations may not be offset by increased revenue.
• A limited market for Subordinate Voting Shares for U.S. holders could affect pricing, transparency, and liquidity.
• Difficulty in locating and obtaining rights to operate at preferred locations due to the federal illegality of cannabis and disadvantaged tax status.
• Exposure to taxation in both Canada and the United States, including classification as a U.S. corporation for federal income tax purposes under IRC Section 7874.
• Higher risk of IRS audit, potentially leading to additional tax, interest, and penalties.
• Lack of United States bankruptcy protections for cannabis businesses could make debt financing more difficult.
• As a holding company, the ability to pay dividends or make other distributions is dependent on subsidiary earnings and subject to legal and contractual restrictions.
• Doubt regarding the ability to enforce contracts due to the federal illegality of cannabis.
• Intense and increasing competition in the cannabis industry from localized businesses and other multi-state operators.
• Limits on the ability to own the necessary cannabis licenses in certain states, restricting organic growth and market share expansion.
• Subsidiaries may not be able to obtain or maintain necessary permits and authorizations, or comply with applicable laws and regulations.
• Inability to accurately forecast operating results and plan operations due to uncertainties and limited reliable market data in the cannabis industry.
• Agricultural and environmental risks inherent in growing cannabis, including losses due to infestation or plant diseases.
• Inability to adequately protect intellectual property due to the federal illegality of cannabis.
• Property is subject to risk of civil asset forfeiture due to the federal illegality of cannabis.
• Dependency on key managerial personnel, including the Chief Executive Officer and Chief Production Officer, and the ability to attract and retain qualified personnel.
• Inherent risks of product liability claims, regulatory action, and litigation related to the use of products.
• Risks related to new products being relatively untested in the marketplace and subject to significant competition.
• Negative impact from unfavorable publicity or consumer perception regarding the safety, efficacy, and quality of medical marijuana products.
• Product recalls due to defects, contamination, or inadequate labeling could result in unexpected expenses, lost sales, and reputational harm.
• Security risks related to products and information technology systems, including theft, privacy breaches, and cyber-attacks.
• Potential criminal prosecution or civil liabilities under the Racketeer Influenced Corrupt Organizations Act (RICO) due to federal illegality of cannabis.
• Significant indebtedness may adversely affect business, financial condition, and financial results.
• Reliance on key utility services, making the business vulnerable to rising energy costs or supply chain disruptions.
• Volatility of the market price and liquidity risks on Subordinate Voting Shares.
• Increased costs as a result of being a U.S. reporting company and subject to various regulatory requirements.
• Concentration risk due to substantial operations in Florida, Arizona, and Pennsylvania, making the company vulnerable to adverse economic conditions or natural disasters in these regions.
• General economic risk from factors like unemployment, interest rates, or inflation influencing consumer trends and spending.
• Inflation risk could adversely impact expenses if costs increase at a higher rate than revenues, affecting profitability.

Future Outlook

The company anticipates continued generation of cash from operations and expects existing cash balances and short-term investments to meet anticipated cash requirements for at least the next 12 months. Future capital requirements are expected to be funded through ongoing operations, debt, or equity financings. The company is monitoring the federal rescheduling process of cannabis to Schedule III and evaluating its potential implications for operations, tax position, and the regulatory environment. Lawmakers in Pennsylvania are expected to introduce adult-use legislation in 2026, and a constitutional amendment to legalize adult-use cannabis in Florida may be on the November 2026 ballot.

Management Comments

• We are committed to delivering exceptional customer experiences through elevated service and high-quality branded products.
• We aim to be the brand of choice for medical and adult-use customers in all of the markets that we serve.
• We are passionate about expanding access to regulated cannabis products through advocacy, education and expansion of our distribution network.
• Our goal is to foster brand loyalty by providing customers with industry-leading branded products and superior service in an appealing, approachable setting.
• We believe infrastructure and data capabilities are prerequisites for long term success in an increasingly competitive and integrated commerce environment.
• We believe our existing cash balances and short-term investments will be sufficient to meet our anticipated cash requirements from the date of filing of this Annual Report on Form 10-K through at least the next 12 months.
• We believe our operations are in material compliance with all applicable state and local laws, regulations, and licensing requirements in the states in which we operate.
• We believe there is a greater likelihood that the IRS will audit the tax returns of cannabis-related businesses.
• We believe its tax position is supportable and that it has substantive legal arguments regarding IRC Section 280E, despite management concluding it does not yet meet the recognition threshold required by ASC 740.
• The Company believes the proposed penalties (from IRS) are without merit and will contest them vigorously.

Industry Context

StockSavvy.ai notes that Trulieve's performance in 2025 reflects a broader trend in the U.S. cannabis industry where multi-state operators are optimizing operations and managing debt amidst a complex and evolving regulatory landscape. The slight revenue dip, coupled with improved net loss and Adjusted EBITDA, suggests a focus on efficiency and profitability over aggressive top-line growth. The significant development of federal cannabis reclassification to Schedule III, driven by President Trump's executive order, is a game-changer for the entire industry, potentially alleviating the onerous 280E tax burden and improving access to traditional financial services. This move could significantly enhance the profitability and investment appeal of companies like Trulieve, which have been operating under severe federal restrictions. The ongoing state-level transitions to adult-use markets, such as in Ohio and potential future shifts in Florida and Pennsylvania, continue to be critical growth catalysts, allowing companies to expand their customer base and revenue streams. However, the fragmented regulatory environment and intense competition remain persistent challenges.

Comparison to Industry Standards

• Trulieve's Adjusted EBITDA margin of 36.2% in 2025 is competitive within the U.S. cannabis MSO sector, often exceeding the average for some peers who may struggle with profitability due to market saturation or high operational costs. For example, while specific peer data for 2025 is not provided, in prior periods, companies like Curaleaf Holdings Inc. (CURLF) and Green Thumb Industries Inc. (GTBIF) have reported Adjusted EBITDA margins that fluctuate, with Trulieve often demonstrating strong operational leverage in its core markets.
• The company's debt management, including the redemption of $368.0 million in 2026 notes and securing new 2030 notes, demonstrates a proactive approach to capital structure, which is crucial in an industry with limited access to traditional banking. This compares favorably to some smaller operators who may face higher refinancing risks or less favorable terms.
• The stock performance graph shows Trulieve's Subordinate Voting Shares (TCNNF) with a total return of (73)% over five years (2020-2025), outperforming its selected peer group (Cresco Labs Inc., Curaleaf Holdings Inc., Green Thumb Industries Inc., Verano Holdings Corp.) which had an average return of (80)%. However, both significantly underperformed the Russell 2000 Index's 34% return, highlighting the broader market's skepticism and federal regulatory overhang on the cannabis sector.
• Trulieve's extensive retail footprint of 233 dispensaries makes it the largest cannabis retailer in the U.S., providing a significant competitive advantage in market penetration and brand recognition compared to regional or single-state operators.

Management Changes

Corporate Governance

Legal Proceedings

• The IRS issued Revenue Agent Reports in September 2025 proposing assessment of taxes, interest, and penalties for some of the company's subsidiaries under audit. Trulieve has submitted protests to dispute these proposed liabilities before the IRS Independent Office of Appeals.
• The company believes its tax position regarding IRC Section 280E is supportable with substantive legal arguments, but management has concluded it does not yet meet the recognition threshold required by ASC 740, leading to $630.3 million in uncertain tax position liabilities.
• The total penalty amount proposed by the IRS, approximately $38.1 million, is not included in the company's uncertain tax position, as the company believes these penalties are without merit and will contest them vigorously.
• There are no actual or, to the company's knowledge, contemplated legal proceedings material to Trulieve or in which any of its property is the subject matter as of December 31, 2025.
• An acquisition in 2021 included a contingency for an additional $5.0 million in consideration, contingent on the enactment of adult-use cannabis laws in Pennsylvania. No liability was recorded as the estimated value was not significant based on the likelihood of approval.

Related Party Transactions

• The company rents an asset from an entity directly owned in part by the CEO and Chair of the board of directors, incurring an expense of $0.3 million in both 2025 and 2024.
• The company leases a cultivation facility and corporate office facility from an entity indirectly owned by the CEO and Chair, a former board member, and a current board member. Lease expense recognized on these related party leases was $0.2 million for 2025, 2024, and 2023.

Stakeholder Impact

• **Shareholders**: Potential for increased value due to improved financial performance (reduced net loss, increased Adjusted EBITDA) and the significant positive impact of potential federal cannabis reclassification. However, dilution risk from future equity issuances and ongoing tax uncertainties remain.
• **Employees**: Continued growth and expansion in new markets (e.g., Texas) could lead to more employment opportunities. The company's commitment to being an 'employer of choice' suggests competitive compensation and development, but the cannabis industry's legal ambiguities could still pose challenges.
• **Customers**: Continued focus on 'Customers First' philosophy, expansion of distribution network, and a curated portfolio of branded products aim to enhance customer experience and loyalty. Adult-use legalization in states like Ohio provides broader access.
• **Suppliers**: Vertical integration in key markets mitigates some third-party risks, but ongoing operations still rely on a supply chain for raw materials, packaging, and other services, indicating continued business for suppliers.
• **Creditors**: Debt refinancing activities, including the redemption of older notes and issuance of new ones, demonstrate active debt management. The potential for federal rescheduling could improve banking access and reduce credit risk over the long term, making the company a more attractive borrower.

Next Steps

• Complete the remaining steps of the licensing process to commence operations in Texas.
• Monitor the federal rescheduling process of cannabis to Schedule III and evaluate its implications.
• Continue to contest the proposed $38.1 million in IRS penalties vigorously.
• Monitor the introduction of adult-use legislation in Pennsylvania in 2026.
• Monitor the initiative petition to place a constitutional amendment to legalize adult-use cannabis on Florida's November 2026 ballot.

Key Dates

Recommendation

Trulieve's 2025 results, while showing a slight revenue dip, demonstrate strong operational efficiency with an improved net loss and increased Adjusted EBITDA. The proactive debt management, including significant redemptions and new financing, strengthens the balance sheet. Most importantly, the federal government's explicit intention to fast-track cannabis reclassification to Schedule III is a monumental catalyst. This move is expected to significantly reduce the company's federal tax burden (IRC 280E) and improve access to traditional banking, unlocking substantial value. While regulatory uncertainties and IRS audits are ongoing, the potential for federal reform, combined with strategic market expansion (e.g., Texas) and a leading retail footprint, positions Trulieve for considerable upside. The stock's historical underperformance relative to the broader market is largely attributable to the federal illegality overhang, which is now showing signs of significant abatement. A seasoned investor would recognize this as a pivotal moment for the industry and a strong 'buy' signal for a market leader like Trulieve.

Keywords

Cannabis, Marijuana, Multi-state operator, MSO, SEC filing, 10-K, Financial results, Adjusted EBITDA, Debt refinancing, Federal rescheduling, Schedule III, Medical cannabis, Adult-use cannabis, Retail cannabis, Cultivation, Manufacturing, Florida, Pennsylvania, Arizona, Texas, Ohio, IRC Section 280E, Regulatory risk, Trulieve